These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28532404)

  • 1. Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform.
    Darwanto A; Hein AM; Strauss S; Kong Y; Sheridan A; Richards D; Lader E; Ngowe M; Pelletier T; Adams D; Ricker A; Patel N; Kühne A; Hughes S; Shiffman D; Zimmermann D; Te Kaat K; Rothmann T
    BMC Cancer; 2017 May; 17(1):358. PubMed ID: 28532404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.
    Gao J; Wu H; Wang L; Zhang H; Duan H; Lu J; Liang Z
    BMJ Open; 2016 Jan; 6(1):e009532. PubMed ID: 26747035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
    Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
    Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.
    Weyn C; Van Raemdonck S; Dendooven R; Maes V; Zwaenepoel K; Lambin S; Pauwels P
    BMC Cancer; 2017 Feb; 17(1):139. PubMed ID: 28201998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical validation of a next generation sequencing testing panel.
    Lüsebrink J; Pieper M; Tillmann RL; Brockmann M; Schildgen O; Schildgen V
    Exp Mol Pathol; 2018 Jun; 104(3):170-174. PubMed ID: 29641993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the GeneReader NGS System in a clinical pathology laboratory: a comparative study.
    Koitzsch U; Heydt C; Attig H; Immerschitt I; Merkelbach-Bruse S; Fammartino A; Büttner RH; Kong Y; Odenthal M
    J Clin Pathol; 2017 Aug; 70(8):725-728. PubMed ID: 28400467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of different massive parallel sequencing platforms for mutation profiling in formalin-fixed and paraffin-embedded samples].
    Jiang RR; Wang YJ; Teng XD; Xiao L; Bu H; Ye F
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):591-596. PubMed ID: 30107663
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study.
    Yoshino T; Muro K; Yamaguchi K; Nishina T; Denda T; Kudo T; Okamoto W; Taniguchi H; Akagi K; Kajiwara T; Hironaka S; Satoh T
    EBioMedicine; 2015 Apr; 2(4):317-23. PubMed ID: 26137573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.
    Gilson P; Franczak C; Dubouis L; Husson M; Rouyer M; Demange J; Perceau M; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(7):e0219204. PubMed ID: 31265477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.
    Ma W; Brodie S; Agersborg S; Funari VA; Albitar M
    Mol Diagn Ther; 2017 Oct; 21(5):571-579. PubMed ID: 28639239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR.
    de Macêdo MP; de Melo FM; Lisboa BC; Andrade LD; de Souza Begnami MD; Junior SA; Ribeiro HS; Soares FA; Carraro DM; da Cunha IW
    Exp Mol Pathol; 2015 Jun; 98(3):563-7. PubMed ID: 25835782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
    Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
    Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GeneReader NGS System Is a Useful Sequencing Platform for Clinical Testing of
    Lee EJ; Kim HK; Ahn S; Lee YJ; Kim J; Lee SW; Lee JW; Lee W; Kim HS; Chun S; Son BH; Jung KH; Kim YM; Min WK; Ahn SH
    Ann Clin Lab Sci; 2020 Jan; 50(1):107-118. PubMed ID: 32161019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QIAGEN Therascreen KRAS RGQ Assay, QIAGEN KRAS Pyro Assay, and Dideoxy Sequencing for Clinical Laboratory Analysis of KRAS Mutations in Tumor Specimens.
    Alqahtani QM; Crowley A; Rapp S; Cushman-Vokoun AM
    Lab Med; 2016 Feb; 47(1):30-8. PubMed ID: 26732779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Biocartis IDYLLA ™ cartridge assay with Qiagen GeneReader NGS for detection of targetable mutations in EGFR, KRAS/NRAS, and BRAF genes.
    Haiduk T; Brockmann M; Tillmann RL; Pieper M; Lüsebrink J; Schildgen V; Schildgen O
    Exp Mol Pathol; 2021 Jun; 120():104634. PubMed ID: 33773991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients.
    Heeke S; Hofman V; Long-Mira E; Lespinet V; Lalvée S; Bordone O; Ribeyre C; Tanga V; Benzaquen J; Leroy S; Cohen C; Mouroux J; Marquette CH; Ilié M; Hofman P
    Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29561830
    [No Abstract]   [Full Text] [Related]  

  • 19. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue.
    Kwon MJ; Lee SE; Kang SY; Choi YL
    Pathol Res Pract; 2011 Dec; 207(12):762-8. PubMed ID: 22070922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
    Laosinchai-Wolf W; Ye F; Tran V; Yang Z; White R; Bloom K; Choppa P; Labourier E
    J Clin Pathol; 2011 Jan; 64(1):30-6. PubMed ID: 21030527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.